Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

2009 Dr. Paul Janssen Award For Biomedical Research Won By Axel Ullrich
Johnson & Johnson has announced that Axel Ullrich, Ph.D., director of the Department of Molecular Biology at the Max Planck Institute of Biochemistry in Germany, whose discoveries have led to novel cancer therapies including Herceptin® (trastuzumab) , is the winner of the 2009 Dr. Paul Janssen Award for Biomedical Research. An independent committee of world-renowned scientists selected Dr. Ullrich, who on September 8 will receive a $100,000 prize during a ceremony in Beerse, Belgium.
generic viagra online
Senate Could Vote Today On Tougher Tobacco Legislation
The Senate could vote today on tougher tobacco laws that would give the Food and Drug Adminstration power to regulate tobacco.
News of the day
Poniard Rally To Continue: Strong Efficacy And Safety Data From Picoplatin
Poniard announced positive Phase II data from its two trials in CRC and CRPC with picoplatin this morning, including efficacy that was comparable to the current standard of care, with a significantly improved safety profile. We believe that these data provide further evidence of picoplatin"s favorable efficacy and safety profile in two more large oncology markets, in addition to SCLC, and position picoplatin as a platform treatment that can provide solutions in multiple oncology settings. We believe that given these data from CRC and CRPC, in addition to the anticipated Phase III SPEAR data in SCLC, will attract the interest of multiple players and we expect that Poniard will be able to at least secure a large pharma partnership sometime this summer, unless a company like Sanofi (SNY Not Rated), Takeda (TKD Not rated), or Bristol-Myers Squibb (BMY Not Rated) decide to step in and acquire the whole company, for rights to both the IV and oral version of picoplatin.
Endocrinology

A Phase III Alzheimer's Drug Increases Levels Of Beta Amyloid In The Brain -- But Still Provides Benefits

Surprising new insights into how a Phase III Alzheimer"s drug might work were among the advances in potential therapies targeting two abnormal brain proteins -- beta amyloid and phosphorylated tau -- that were reported today at the Alzheimer"s Association 2009 International Conference on Alzheimer"s Disease (ICAD 2009) in Vienna. Scientists also reported on how clinicians view and treat mild cognitive impairment (MCI), a research category used to define the state between normal aging and Alzheimer"s, that is now being used widely in clinical practice. "There are now more than 26 million people living with Alzheimer"s and dementia around the world. The cost of caring for these people, and those who will get it in the next few years, will bankrupt the world"s healthcare systems," said Ralph Nixon, PhD, MD, vice chair of the Alzheimer"s Association Medical & Scientific Advisory Council. "But, as these studies and many hundreds more reported at ICAD 2009 show, there is hope. There are currently dozens of drugs in clinical trials for Alzheimer"s. This, combined with advancements in diagnostic tools, has the potential to change the landscape of Alzheimer"s in our lifetime. How fast we get there depends completely on the investment in research. We need more government and private dollars for Alzheimer"s research now to capitalize on the progress we"ve made in the last decade," Nixon added. The studies reported at ICAD 2009 were: -- Sam Gandy, et al -- Dimebon(R), A Clinically Promising Drug For Alzheimer Disease, Regulates Amyloid-Beta Metabolism In Cultured Cells, In Isolated Nerve Terminals, And In The Interstitial Fluid Of The Living Rodent Brain. -- Moran Boimel, et al -- Immunotherapy Targeting Pathologically Phosphorylated Tau In A Tauopathy Mouse Model. -- Scott Roberts, et al -- Clinical Practices Regarding Mild Cognitive Impairment (MCI) Among Neurology Service Providers. The 2009 Alzheimer"s Association International Conference on Alzheimer"s Disease (ICAD 2009) brings together more than 3,000 researchers from 70 countries to share groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer"s disease and related disorders. ICAD 2009 will be held in Vienna, Austria at Messe Wien Exhibition and Congress Center from July 11-16. The Alzheimer"s Association is the leading voluntary health organization in Alzheimer care, support and research. Our mission is to eliminate Alzheimer"s disease through the advancement of research, to provide and enhance care and support for all affected, and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer"s. For more information, visit http://www.alz.org. Alzheimer"s Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009